-
1.发明申请SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 审中-公开取代的N-（1H-咪唑-4-基）咪唑并[1,2-a]吡啶-3-羧酸酰胺化合物作为III型受体酪氨酸激酶抑制剂
公开(公告)号：WO2012082689A1
公开(公告)日：2012-06-21
申请号：PCT/US2011/064549
申请日：2011-12-13
Applicant: ARRAY BIOPHARMA INC. , BOYS, Mark Laurence , DELISLE, Robert Kirk , HICKEN, Erik James , KENNEDY, April L. , MARESKA, David A. , MARMSATER, Fredrik P. , MUNSON, Mark C. , NEWHOUSE, Brad , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
Inventor： BOYS, Mark Laurence , DELISLE, Robert Kirk , HICKEN, Erik James , KENNEDY, April L. , MARESKA, David A. , MARMSATER, Fredrik P. , MUNSON, Mark C. , NEWHOUSE, Brad , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
IPC: C07D471/04 , A61K31/437 , A61P35/00
CPC classification number: C07D471/04 , A61K31/496 , A61K45/06
Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
Abstract translation: 式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和R 6具有说明书中给出的含义，是cFMS的抑制剂，可用于治疗纤维化，骨相关疾病，癌症 ，自身免疫性疾病，炎性疾病，心血管疾病，哺乳动物的疼痛和灼伤。
-
公开(公告)号：WO2010022076A1
公开(公告)日：2010-02-25
申请号：PCT/US2009/054193
申请日：2009-08-18
Applicant: ARRAY BIOPHARMA INC. , ALLEN, Shelley , CELESTE, Laura L. , DAVIS, T. Gregg , DELISLE, Robert Kirk , GRESCHUK, Julie Marie , GROSS, Stefan, D. , HICKEN, Erik, James , JACKSON, Leila, J. , LYSSIKATOS, Joseph, P. , KALLAN, Nicholas C. , MARMSATER, Fredrik, P. , MUNSON, Mark, C. , PHENEGER, Jed , RAST, Bryson , ROBINSON, John, E. , SCHLACHTER, Stephen T. , TOPALOV, George T. , WRIGHT, A. Dale , ZHAO, Qian
Inventor： ALLEN, Shelley , CELESTE, Laura L. , DAVIS, T. Gregg , DELISLE, Robert Kirk , GRESCHUK, Julie Marie , GROSS, Stefan, D. , HICKEN, Erik, James , JACKSON, Leila, J. , LYSSIKATOS, Joseph, P. , KALLAN, Nicholas C. , MARMSATER, Fredrik, P. , MUNSON, Mark, C. , PHENEGER, Jed , RAST, Bryson , ROBINSON, John, E. , SCHLACHTER, Stephen T. , TOPALOV, George T. , WRIGHT, A. Dale , ZHAO, Qian
IPC: C07D471/04 , A61K31/47
CPC classification number: C07D471/04
Abstract: Compounds of Formula (I), in which A, B, R 1 , R 1a , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
Abstract translation: 其中A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有本说明书中给出的含义的式（I）化合物是可用于治疗免疫细胞相关的受体酪氨酸抑制剂 疾病和病症，如炎性和自身免疫性疾病。
-
公开(公告)号：WO2006125101A2
公开(公告)日：2006-11-23
申请号：PCT/US2006019280
申请日：2006-05-18
Applicant: ARRAY BIOPHARMA INC , LAIRD ELLEN , TOPALOV GEORGE , LYSSIKATOS JOSEPH P , WELCH MIKE , GRINA JONAS , HANSEN JOSH , NEWHOUSE BRAD
Inventor： LAIRD ELLEN , TOPALOV GEORGE , LYSSIKATOS JOSEPH P , WELCH MIKE , GRINA JONAS , HANSEN JOSH , NEWHOUSE BRAD
CPC classification number: C07D487/04
Abstract: Compounds of Formula (I) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula (I), and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract translation: 式（I）的化合物可用于抑制Raf激酶和用于治疗由此介导的病症。 公开了使用式（I）化合物及其立体异构体，互变异构体，溶剂合物及其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理学病症中的这种病症的方法 。
-
4.发明申请SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS 审中-公开取代的吡唑并[1,5-a]吡啶化合物作为mTOR抑制剂
公开(公告)号：WO2011029027A1
公开(公告)日：2011-03-10
申请号：PCT/US2010/047856
申请日：2010-09-03
Applicant: ARRAY BIOPHARMA INC. , ANDREWS, Steven W. , CONDROSKI, Kevin Ronald , DE MEESE, Lisa A. , FELL, Jay Bradford , FISCHER, John P. , LE HUEROU, Yvan , JOSEY, John A. , KOCH, Kevin , MIKNIS, Gregory F. , RODRIGUEZ, Martha E. , TOPALOV, George T. , WALLACE, Eli M. , XU, Rui
Inventor： ANDREWS, Steven W. , CONDROSKI, Kevin Ronald , DE MEESE, Lisa A. , FELL, Jay Bradford , FISCHER, John P. , LE HUEROU, Yvan , JOSEY, John A. , KOCH, Kevin , MIKNIS, Gregory F. , RODRIGUEZ, Martha E. , TOPALOV, George T. , WALLACE, Eli M. , XU, Rui
IPC: C07D487/04 , A61K31/519
CPC classification number: C07D487/04
Abstract: Compounds of Formula I: and salts thereof in which R 1 , R 2 , R 2a , R 3 , n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.
Abstract translation: 式I化合物及其盐，其中R 1，R 2，R 2a，R 3，n，X和环B具有本说明书中给出的含义，是mTOR的抑制剂，可用于治疗对抑制作用敏感的疾病 mTOR，如癌症。
-
5.发明申请IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS 审中-公开咪唑并[1,2-A]吡啶化合物作为受体酪氨酸激酶抑制剂
公开(公告)号：WO2008124323A1
公开(公告)日：2008-10-16
申请号：PCT/US2008/058395
申请日：2008-03-27
Applicant: ARRAY BIOPHARMA INC. , ALLEN, Shelley , GRESCHUK, Julie, Marie , KALLAN, Nicholas, C. , MARMSÄTER, Fredrik, P. , MUNSON, Mark, C. , RIZZI, James, P. , ROBINSON, John, E. , SCHLACHTER, Stephen, T. , TOPALOV, George, T. , ZHAO, Qian , LYSSIKATOS, Joseph, P.
Inventor： ALLEN, Shelley , GRESCHUK, Julie, Marie , KALLAN, Nicholas, C. , MARMSÄTER, Fredrik, P. , MUNSON, Mark, C. , RIZZI, James, P. , ROBINSON, John, E. , SCHLACHTER, Stephen, T. , TOPALOV, George, T. , ZHAO, Qian , LYSSIKATOS, Joseph, P.
IPC: C07D471/04 , A61K31/33 , A61P35/00
CPC classification number: C07D471/04
Abstract: Compounds of Formula I: in which A, B, R 1 , R 1a , R 2 , R 3 , R 4 , R 5 R 6 , R 7 and R 8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.
Abstract translation: 式I化合物：其中A，B，R 1，R 1a，R 2，R 3， R 4，R 5，R 6，R 7和R 8都具有 说明书中给出的含义是可用于治疗由3类和5类受体酪氨酸激酶介导的疾病的受体酪氨酸抑制剂。 本发明的具体化合物也被发现是Pim-1的抑制剂。
-
Patent Agency Ranking6.发明申请IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS 审中-公开咪唑并[1,2-A]吡啶化合物作为受体酪氨酸激酶抑制剂
公开(公告)号：WO2008121687A2
公开(公告)日：2008-10-09
申请号：PCT/US2008058385
申请日：2008-03-27
Applicant: ARRAY BIOPHARMA INC , MARMSAETER FREDRIK P , MUNSON MARK C , RIZZI JAMES P , ROBINSON JOHN E , SCHLACHTER STEPHEN T , TOPALOV GEORGE T , ZHAO QIAN , LYSSIKATOS JOSEPH P
Inventor： MARMSAETER FREDRIK P , MUNSON MARK C , RIZZI JAMES P , ROBINSON JOHN E , SCHLACHTER STEPHEN T , TOPALOV GEORGE T , ZHAO QIAN , LYSSIKATOS JOSEPH P
IPC: C07D471/04 , A61K31/4709 , A61P35/00
CPC classification number: C07D471/04
Abstract: Compounds of Formula (I) in which A, B, R 1 , R 1a , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.
Abstract translation: 其中A，B，R 1，R 1a，R 2，R 3，O 3的式（I）化合物 R 4，R 5，R 6，R 7和R 8，R 8， >具有说明书中给出的含义，是可用于治疗由3类和5类受体酪氨酸激酶介导的疾病的受体酪氨酸抑制剂。 本发明的具体化合物也被发现是Pim-1的抑制剂。
-
7.发明申请SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS 审中-公开取代的N-（1H-吲唑-4-基）咪唑并[1,2-A]吡啶-3-羧酰胺化合物作为CFMS抑制剂
公开(公告)号：WO2011079076A1
公开(公告)日：2011-06-30
申请号：PCT/US2010/061341
申请日：2010-12-20
Applicant: ARRAY BIOPHARMA INC. , BOYS, Mark Laurence , BRADLEY, Michael , DELISLE, Robert Kirk , HENNINGS, D. David , KENNEDY, April L. , MARMSATER, Fredrik P. , MEDINA, Matthew , MUNSON, Mark C. , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
Inventor： BOYS, Mark Laurence , BRADLEY, Michael , DELISLE, Robert Kirk , HENNINGS, D. David , KENNEDY, April L. , MARMSATER, Fredrik P. , MEDINA, Matthew , MUNSON, Mark C. , RAST, Bryson , RIZZI, James P. , RODRIGUEZ, Martha E. , TOPALOV, George T. , ZHAO, Qian
IPC: C07D471/04 , C07D519/00 , A61K31/437 , A61K31/4985 , A61P9/00 , A61P19/08 , A61P29/00 , A61P35/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.
Abstract translation: 其中R1，R2，R3，R4和R5具有本说明书中给出的含义的式（I）化合物及其药学上可接受的盐是cFMS的抑制剂，可用于治疗骨相关疾病，癌症，自身免疫 疾病，炎性疾病，心血管疾病和疼痛。
-
公开(公告)号：WO2008121687A3
公开(公告)日：2008-10-09
申请号：PCT/US2008/058385
申请日：2008-03-27
Applicant: ARRAY BIOPHARMA INC. , MARMSÄTER, Fredrik, P. , MUNSON, Mark, C. , RIZZI, James, P. , ROBINSON, John, E. , SCHLACHTER, Stephen, T. , TOPALOV, George, T. , ZHAO, Qian , LYSSIKATOS, Joseph, P.
Inventor： MARMSÄTER, Fredrik, P. , MUNSON, Mark, C. , RIZZI, James, P. , ROBINSON, John, E. , SCHLACHTER, Stephen, T. , TOPALOV, George, T. , ZHAO, Qian , LYSSIKATOS, Joseph, P.
IPC: C07D471/04 , A61K31/4709 , A61P35/00
Abstract: Compounds of Formula (I): are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class (3) and class (5) receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.
-
公开(公告)号：WO2006125101A3
公开(公告)日：2006-11-23
申请号：PCT/US2006/019280
申请日：2006-05-18
Applicant: ARRAY BIOPHARMA INC. , LAIRD, Ellen , TOPALOV, George , LYSSIKATOS, Joseph, P. , WELCH, Mike , GRINA, Jonas , HANSEN, Josh , NEWHOUSE, Brad
Inventor： LAIRD, Ellen , TOPALOV, George , LYSSIKATOS, Joseph, P. , WELCH, Mike , GRINA, Jonas , HANSEN, Josh , NEWHOUSE, Brad
IPC: C07D487/04 , A61K31/4985 , A61P35/00
Abstract: Compounds of Formula (I) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula (I), and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号：WO2005016346A1
公开(公告)日：2005-02-24
申请号：PCT/US2004/026235
申请日：2004-08-10
Applicant: ARRAY BIOPHARMA INC. , WALLACE, Eli , TOPALOV, George , LYSSIKATOS, Joseph , BUCKMELTER, Alexandre , ZHAO, Qian
Inventor： WALLACE, Eli , TOPALOV, George , LYSSIKATOS, Joseph , BUCKMELTER, Alexandre , ZHAO, Qian
IPC: A61K31/51
CPC classification number: C07D239/94 , C04B35/632 , C07D401/12 , C07D413/12 , C07D413/14 , C07D417/14
Abstract: This invention provides quinazoline analogs of Formula (I): where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R 3 groups. The invention also includes methods of using compounds of Formula (I) as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Abstract translation: 本发明提供式（I）的喹唑啉类似物：其中A与双环的5,6,7或8位上的至少一个碳键合，并且该环被至多两个独立的R 3取代 >组。 本发明还包括使用式（I）化合物作为I型受体酪氨酸激酶抑制剂并用于治疗过度增殖性疾病如癌症的方法。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.028 seconds)
